Resource Logo
NLM AIDSLINE

Intraventricular administration of a FIV-envelope protein induces sleep architecture changes in rats.




 

Brain Res. 1994 Oct 3;659(1-2):254-8. Unique Identifier : AIDSLINE

Fifteen adult male Sprague-Dawley rats were implanted with a set of electrodes for standard sleep recordings. A stainless steel cannula was also implanted into the lateral ventricle of these rats. Fifteen additional rats were implanted with a cannula alone. Rats with electrodes were habituated for 3 days or more to the recording environment, then placed into 3 groups (n = 5). One group received saline (i.c.v.), while the other two groups received either the feline immunodeficiency virus envelope glycoprotein (FIV SU-Env) or a fragment of the Epstein-Barr virus envelope glycoprotein (EB gp105). Rats were then recorded for electrographic sleep-wake cycle evaluation for the following 4 h. Core temperature was assessed through a thermistor probe inserted into the rectum, immediately before and 1, 2, 3 and 4 h after the i.c.v. treatment condition. Results demonstrated that compared to saline, FIV SU-Env increased wakefulness and decreased REM sleep throughout the 4 h of recording. Likewise, FIV SU-Env decreased SWS2 for 2 h. In addition, EB gp105 administration elicited minor modifications of the sleep-wake cycle, causing only a transient reduction of REM sleep in the first hour of recording. None of the treatments altered body temperature. These findings strongly support and extend studies in FIV-infected cats in which we have found similar sleep abnormalities. In addition, these results are consistent with the hypothesis that the FIV SU-Env proteins are responsible for these neurological disturbances.(ABSTRACT TRUNCATED AT 250 WORDS)

Animal Brain/*PHYSIOLOGY Electroencephalography Gene Products, gag/*ADMINISTRATION & DOSAGE/PHARMACOLOGY Injections, Intraventricular Male Peptide Fragments/ADMINISTRATION & DOSAGE/PHARMACOLOGY Rats Rats, Sprague-Dawley Sleep Stages/*DRUG EFFECTS Support, U.S. Gov't, P.H.S. Viral Envelope Proteins/*ADMINISTRATION & DOSAGE/PHARMACOLOGY Wakefulness/DRUG EFFECTS JOURNAL ARTICLE



 




Information in this article was accurate in April 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.